Aqeel Mandviwala, MD
Pulmonary Disease · London, KYNPI 1326016460
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 513 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 513 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- GSK$1K
- Grifols USA, LLC$913
- Mylan Specialty L.p.$612
- Sanofi$487
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$5105%
- Food & beverage$10,13492%
- Education$3403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $2,221 |
| Boehringer Ingelheim | 90 | $1,840 |
| GSK | 89 | $1,464 |
| Grifols USA, LLC | 36 | $913 |
| Mylan Specialty L.p. | 30 | $612 |
| Sanofi | 24 | $487 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $410 |
| Pfizer | 22 | $349 |
| Harmony Biosciences LLC | 10 | $216 |
| Insmed, Inc. | 11 | $212 |
| Axsome Therapeutics, Inc. | 9 | $205 |
| Genentech USA, Inc. | 11 | $197 |
| Amgen | 6 | $196 |
| Pulmonx Corporation | 2 | $187 |
| Actelion Pharmaceuticals US, Inc. | 5 | $186 |
| Sunovion Pharmaceuticals Inc. | 11 | $169 |
| Grifols Shared Services North America, Inc. | 1 | $145 |
| Mallinckrodt Hospital Products Inc. | 3 | $126 |
| Intuitive Surgical | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $102 |
| Electromed, Inc. | 6 | $91 |
| Philips North America LLC | 5 | $86 |
| Verona Pharma, Inc. | 4 | $85 |
| Circassia Inc. | 4 | $70 |
| Viatris Specialty LLC | 3 | $57 |
| Shire North American Group Inc | 3 | $44 |
| Merck | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| AbbVie | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| CSL Behring | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C Liquid$270
- DUPIXENT$250
- BREZTRI$250
- TEZSPIRE$249
- Pulmonx Endobronchial Valve EBV$175
- AIRSUPRA$125
- Da Vinci Surgical System$125
- Yupelri$113
- NUCALA$107
How this compares
$10,983 in reported general payments places this provider in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $340,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $254,458 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $237,382 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $184,004 |
| Spiriva RespimatTiotropium Bromide | 235 | $159,461 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 196 | $130,428 |
| TezspireTezepelumab-Ekko | 21 | $92,596 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $82,767 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 149 | $80,545 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 134 | $79,583 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $72,769 |
| XolairOmalizumab | 17 | $50,056 |
| Dupixent PenDupilumab | 11 | $42,053 |
| SymbicortBudesonide/Formoterol Fumarate | 104 | $38,676 |
| NucalaMepolizumab | 11 | $38,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,840 | $593,772431 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $1,464 | $460,677653 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $2,221 | $271,936348 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $410 | $184,00412 claims |
| Grifols USA, LLCProlastin C | $913 | $82,76712 claims |
| MerckDulera, Belsomra | $33 | $23,63648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in London
- Abdul SiddiquiLondon$16K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
- Dennis DohertyLexington$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.